Clinical trials
Prostate Cancer Stage clinical trials
Below are recruiting prostate cancer stage clinical trials, each written for real people, not researchers. We’re tracking 410 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06965192Recruiting
Visual tools for cancer surgeon decision-making
This trial tests visual tools to help surgeons make better decisions for patients with early-stage prostate or kidney cancer. It may help you and your doctor choose the best treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT07089550Recruiting
PSMA PET scans to track treatment response in advanced prostate cancer
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Bologna, ItalyAges 18 years+ - NCT06866041Recruiting
Prostate cancer markers and imaging for low-risk patients on active surveillance
This trial looks for new markers and advanced scans to better predict which low-risk prostate cancers might grow. If you have low-risk prostate cancer and are managing it with active surveillance, researchers want to see if PSMA-PET scans and tissue markers can give earlier warning of progression.
Milan, ItalyAges 45–80 - NCT04083937Recruiting
Radiation after prostate surgery for men with prostate cancer
This study looks at different radiation approaches after prostate surgery to see which strategy works best. You may be able to join if your cancer is at a stage where radiation to the prostate bed is planned, and you have not had prior radiation.
HeidelbergAges 18 years+ - NCT05348876RecruitingPhase 4
Darolutamide plus standard hormone therapy for high-risk prostate cancer
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
Vijayawada, Andhra PradeshAges 18 years+ - NCT06960798Recruiting
Prostate cancer genetics study in Native Americans
This study looks at the genes of prostate cancer in Native American people. It aims to learn more about the disease in this population by testing stored tumor samples. You can join if you have a prostate cancer diagnosis and have a tumor sample available.
Oklahoma City, OklahomaAges 18–100 - NCT03459820Enrolling by invitationPhase 2/Phase 3
PET/CT scan study for high-risk or returning prostate cancer
This trial studies how a special PET/CT scan (using 18F-DCFPyL) helps evaluate prostate cancer that is either high-risk at diagnosis or has come back based on PSA blood tests. It may help your care team better stage (map) the cancer and guide next steps.
Montreal, QuebecAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06439693RecruitingPhase 2
Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Boston, MassachusettsAges 18 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Phoenix, ArizonaAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT06282588RecruitingPhase 2/Phase 3
Advanced imaging-guided treatment for high-risk prostate cancer
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
Wilrijk, AntwerpAges 18 years+ - NCT06594926RecruitingPhase 2
Bipolar androgen therapy for prostate cancer without metastases
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06476119Recruiting
Optimizing treatment for low stage triple-negative breast cancer with high immune cells
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
Sittard-Geleen, LimburgAges 18 years+ - NCT04212715RecruitingPhase 2
Extra radiation boost for high-risk prostate cancer
This Phase 2 study tests a treatment plan that uses standard focused radiation to the prostate, plus an extra “boost” delivered inside the prostate. It may help improve control of high-risk prostate cancer, especially by aiming radiation more precisely.
RiyadhAges 18–99 - NCT06461819RecruitingPhase 2
Higher radiation dose for low-to-intermediate prostate cancer
This trial tests if giving a higher dose of radiation in fewer sessions, while using SpaceOAR to protect the rectum, is safe for men with low-to-intermediate risk prostate cancer that hasn't spread.
SeoulAges 20 years+ - NCT04732156Recruiting
Test AI and MRI scores to spot prostate cancer
This study compares how well a doctor’s MRI reading (the PI-RADS score) and a computer AI tool detect prostate cancer. It may help improve how men get targeted biopsies and avoid missing important cancers.
BordeauxAges 18–80 - NCT06429696RecruitingPhase 2
Maintenance therapy for extensive stage small cell lung cancer
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT06773156Enrolling by invitationPhase 2
Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Nanchang, JiangxiAges 18–75 - NCT05613023RecruitingPhase 3
Short-course prostate and pelvic SBRT using 5 treatment sessions
This study compares two schedules of highly focused radiation (SBRT): 5 sessions to the prostate only, versus 5 sessions to the prostate and nearby pelvic lymph nodes. It aims to see which approach controls high-risk localized prostate cancer better while you also take hormone therapy.
CorkAges 18 years+ - NCT06768931RecruitingPhase 2
Combination therapy before surgery for triple-negative breast cancer
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
Lanzhou, GansuAges 18 years+ - NCT07050394RecruitingEarly Phase 1
Experimental drug for advanced colorectal cancer
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
Shanghai, None SelectedAges 18 years+
Hear when a new Prostate Cancer Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer stage?
- Yes. Clin2 currently lists 410 recruiting prostate cancer stage studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer stage trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer stage trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.